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Medicines: Effectiveness or cost
To the Editor: Regarding the article by Chris Bateman,1 I was 
horrified to see that I am readily identifiable as the journalist’s 
‘source’, as I had officially withdrawn and dissociated myself 
from all aspects of the article. The article is flawed and does not 
reflect the collegial nature of the discussions at provincial and 
national levels. It is ironic that the article attempts to debate 
the ethics of breast cancer drug allocation – but there has been 
a lack of ethical due-process in its publication. The lack of peer 
review is highlighted by the spelling of one of the prominent 
agents involved (i.e. the taxanes), which are spelt ‘texanes’ 
throughout the article.
This letter, however, allows me the opportunity to highlight 
the need for a formal review process for medicines in a 
resource-constrained health care sector, such as our own.
The way in which medicines are usually evaluated in 
the various sectors in South Africa is based on two criteria: 
effectiveness and cost. However, in reality, decisions are 
invariably based on expert opinion. Unfortunately, the 
emphasis is usually on either effectiveness or cost, and 
hardly ever on a systematic analysis that incorporates 
both considerations. There are a number of reasons for 
this behaviour: (i) lack of appreciation of the role of cost-
effectiveness analysis in decision making; (ii) scarcity or 
absence of individuals with the necessary critical appraisal 
skills; and (iii) a short-term view of the consequences of health 
care decisions.
It is imperative that this kind of independent systematic 
analysis takes place for all medicines, so ensuring access, an 
equitable distribution of resources, and justice in the health 
care industry. Such a process will go a long way towards 
establishing an appropriate standard of clinical excellence, 
open to scrutiny. This is a critical ethical imperative in a 
resource-constrained health care system such as South Africa’s, 
and for societal trust in the process.
Marc Blockman
Department of Internal Medicine
Division of Clinical Pharmacology
University of Cape Town and Groote Schuur Hospital
blockman@mweb.co.za
1.    Bateman C. Vital breast cancer drugs highlight funding ethics. S Afr Med J 2008; 98: 833-836.
Unhygienic male circumcision  
procedures and HIV transmission
To the Editor: Connolly and colleagues report one of the most 
detailed observational investigations of the association between 
male circumcision and HIV infection in sub-Saharan Africa to 
date.1 They found no overall association between circumcision 
and prevalent HIV infection in South Africans. Connolly and 
colleagues also suspect that the often unhygienic circumcision 
procedures among black South Africans may facilitate HIV 
transmission.  
Evidence from Kenya, Lesotho and Tanzania is consistent 
with this hypothesis.2  Circumcised males in these countries 
are typically circumcised in adolescence or early adulthood. 
In each country, circumcised virgins were substantially more 
likely to be HIV infected than sexually experienced males. 
Similarly, circumcised adolescent males were more likely 
to be infected than their uncircumcised counterparts. (In 
Lesothoan young men circumcision was also associated with 
HIV infection, perhaps reflecting an older age at circumcision 
for Lesothoans than for Kenyans and Tanzanians.) However, 
in older age groups circumcised men were less likely to be 
infected than uncircumcised men. This pattern could partially 
be explained by increased mortality among circumcised 
adolescents and young adults (due to circumcision-related 
HIV infection), thus reducing HIV prevalence (or slowing its 
growth) relative to uncircumcised men in older age groups.2 
A delayed protective effect of circumcision, HIV-specific 
immunity acquired from circumcision-related exposures, and 
other factors might also account for this pattern. 
For decades, substantial fractions of youth throughout 
southern and eastern Africa have identified circumcision as a 
risk for HIV transmission.2-10 It is therefore crucial that more 
rigorous investigations beyond analyses of cross-sectional data 
be conducted to resolve the matter with confidence.2 Future 
work might include detailed observations of circumcision 
procedures in different settings combined with prospective 
studies of adolescent and young adult males in communities 
where circumcision is common.  Intervention trials of safer 
circumcision (compared with existing procedures) might also 
provide critical evidence, as might sequencing of infected 
youths’ HIV DNA in both observational and intervention 
studies that focus on circumcision in specific communities.
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